![]() |
A review on potassium iodide in radiological disasters...
April 1, 2017 - Featured , In the News / Politics By: Victoria Hom, PharmD Candidate c/o 2018 – This year marked the 31st anniversary of Chernobyl, the worst nuclear disaster in history due to a malfunctioned reactor operated by inadequately trained staff. The accident’s explosion released a large plume of iodine-131, one of many radioactive substances, into the atmosphere, which prompted an evacuation around the… |
![]() |
Biosimiliars: how will they affect the pharmacoeconomic...
April 1, 2017 - Featured , In the News / Politics By: Kenny Chan, PharmD – Competition is the greatest driver of innovation and cost savings. The U.S. health care system relies heavily on generic medications to reduce the cost of drug spending. Since the Hatch-Waxman Act of 1984, generic versions of chemically synthesized, “small molecule” drugs have dominated the market and contributed to over 80%… |
![]() |
Goodbye pharmacists, hello robots?...
April 1, 2017 - Featured , Professional Advice / Opinions By: Katherine Russo, PharmD Candidate c/o 2021 – “Treat the whole patient and not the whole in the patient” – Unknown From the new temporal scanner thermometers in your local pediatrician’s office, to needle-free diabetes care at home, to medication dispensing boxes in hospitals, the ever-evolving world of technology is no stranger to the healthcare… |
![]() |
Lifitegrast: an alternative treatment for dry eye disea...
April 1, 2017 - Featured , In the News / Politics By: Vicky Liu, PharmD Candidate c/o 2018 – On July 11, 2016, lifitegrast (Xiidra®), the first lymphocyte function-associated antigen 1 (LFA-1), was approved by FDA for the treatment of the signs and symptoms of dry eye disease. The risk for patients to develop dry eye syndrome increases with age, occurring in 5% of adults ages… |
![]() |
The function and efficacy of pimavanserin (Nuplazid®) ...
April 1, 2017 - Clinical , Featured By: Jonathan Mercado, PharmD Candidate c/o 2019 – In April 2016, the FDA approved the first drug specifically indicated for the symptoms of psychosis associated with Parkinson’s disease (PDP).1 Currently, clozapine and quetiapine are used off label to treat symptoms associated with Parkinson disease such as voices in patients’ heads, various hallucinations and delusions. In… |
![]() |
Two hepatitis C drugs approved for pediatric use...
April 1, 2017 - Featured , In the News / Politics By: Anna Diyamandoglu, PharmD Candidate c/o 2020 – Hepatitis C is an infectious disease which is caused by the hepatitis C virus (HCV) and is characterized by inflammation of the liver. Its effects on the body range from a mild illness that lasts several weeks to a chronic illness that attacks the liver and affects… |